Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome.
Safety and immunogenicity of a booster dose of 7-valent pneumococcal conjugate vaccine (PCV7) were evaluated in 29 patients with idiopathic nephrotic syndrome (INS), who had been primed 12 months earlier with one dose of PCV7. PCV7 was not associated with increased risk of INS relapse (RR=0.77, p=0.8) and serotype-specific antibodies increased in all subjects at 1 month (p<0.01). The quantitative characteristics of immune response and the effect of treatment with mycophenolate mofetil and/or cyclosporine A following booster PCV7 were similar with primary response. Additional PCV7 doses could be safely given in children with INS to increase circulating antibodies above the protective threshold.
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece. Electronic address: chrisliakou_med@hotmail.com.
Christina D
CD
Liakou
Department of Nephrology, "P. and A. Kyriakou" Children's Hospital, Athens, Greece.
Varvara
V
Askiti
Department of Nephrology, "P. and A. Kyriakou" Children's Hospital, Athens, Greece.
Andromachi
A
Mitsioni
Department of Nephrology, "P. and A. Kyriakou" Children's Hospital, Athens, Greece.
Constantinos J
CJ
Stefanidis
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece.
Maria C
MC
Theodoridou
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece.
Vana I
VI
Spoulou
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000628:therapy*; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011446:Prospective Studies
D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D022242:Pneumococcal Vaccines; D016572:Cyclosporine; D009173:Mycophenolic Acid
Booster vaccination; Idiopathic nephrotic syndrome; Pneumococcal conjugate vaccine; Safety